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Abstract
Our study investigated the association of rare allelic variants with extremes of 24-hour urinary calcium excretion because
higher urinary calcium excretion is a dominant risk factor for calcium-based kidney stone formation. We resequenced 40
candidate genes potentially related to urinary calcium excretion in individuals from the Nurses’ Health Studies I & II and the
Health Professionals Follow-up Study. A total of 960 participants were selected based on availability of 24-hour urine
collection data and level of urinary calcium excretion (low vs. high). We utilized DNA sample pooling, droplet-based target
gene enrichment, multiplexing, and high-throughput sequencing. Approximately 64% of samples (n=615) showed both
successful target enrichment and sequencing data with .20-fold deep coverage. A total of 259 novel allelic variants were
identified. None of the rare gene variants (allele frequencies ,2%) were found with increased frequency in the low vs. high
urinary calcium groups; most of these variants were only observed in single individuals. Unadjusted analysis of variants with
allele frequencies $2% suggested an association of the Claudin14 SNP rs113831133 with lower urinary calcium excretion (6/
520 versus 29/710 haplotypes, P value=0.003). Our data, together with previous human and animal studies, suggest a
possible role for Claudin14 in urinary calcium excretion. Genetic validation studies in larger sample sets will be necessary to
confirm our findings for rs113831133. In the tested set of candidate genes, rare allelic variants do not appear to contribute
significantly to differences in urinary calcium excretion between individuals.
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Introduction
Kidney stone disease is a major cause of morbidity associated
with tremendous pain, suffering, and substantial economic impact
[1–3]. The majority of kidney stones contain calcium, most
commonly in the form of calcium (Ca
2+) oxalate. Higher urinary
Ca
2+ excretion is associated with higher risk of calcium-containing
kidney stone formation. The etiology of the vast majority of cases
of hypercalciuria is unknown and is referred to as idiopathic
hypercalciuria [4].
Nephrolithiasis is a multifactorial disease with genetic and
environmental factors determining the likelihood of stone forma-
tion [5]. We and other investigators have identified multiple
environmental risk factors associated with increased risk including
lower dietary Ca
2+ intake [6–8], lower fluid intake [6–9], and
higher body mass index [8,10]. A family history of nephrolithiasis
is associated with a greater than two-fold increase in the risk of
developing a stone [11]. Substantial data demonstrate that
calcium-based kidney stones and elevated urinary Ca
2+ are linked
and likely have a strong genetic component [12]. Genes for rare
Mendelian forms of nephrolithiasis and increased urinary Ca
2+
excretion have been identified; however, mutations in these genes
explain only a very small fraction of kidney stone disease in the
general population. For example, mutations in the renal chloride
channel CLCN5 cause Dent’s disease, a group of X-linked
hypercalciuric abnormalities [13]. Inactivating (loss-of-function)
mutations in the calcium-sensing receptor (CaSR) cause autoso-
mal-dominant hypocalcemia and hypercalciuria [14]. Another
example is familial hypomagnesemia associated with hypercalci-
uria and nephrocalcinosis (mutations in Claudin16) [15]. Addi-
tional genes were identified in various animal models such as the
renal epithelial Ca
2+ transporter gene (TRPV5), which when
mutated causes severe hypercalciuria in the mouse [16].
Rather than testing the ‘‘common disease, common variant’’
hypothesis pursued by genome wide association studies (GWAS),
our approach tested the association of the frequencies of rare
genetic variants with 24-hour urinary Ca
2+ excretion [17]. This
approach has succeeded when examining other complex traits
such as hypertriglyceridemia [18], hypercholesterolemia [19], and
non-alcoholic fatty liver disease [20]. The findings in these studies
were consistent with in silico predictions that some sequence
variations found in healthy individuals are as deleterious to protein
function as mutations that, in other genes, cause monogenic
disease. Highly penetrant rare alleles may be an important genetic
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e71885contributor to common disease seen in the general population as
shown for blood pressure variation [21].
The goal of this work was to identify rare, functionally
significant genetic variants associated with urinary Ca
2+ excretion.
Forty candidate genes possibly related to urinary Ca
2+ excretion
were resequenced at extremes of urinary Ca
2+ excretion in 960
individuals from three well-characterized cohorts, the Nurses’
Health Studies (NHS) I & II and the Health Professional Follow-
Up Study (HPFS).
Methods
A. Study cohorts
The NHS I was established in 1976 with over 120,000 female
registered nurses aged 30–55 years. The NHS II was established in
1989 with over 116,000 female nurses aged 25–42 years. The
HPFS was established in 1986 with over 51,000 male health care
professionals aged 40–75 years. All three cohorts have been
followed by biennially mailed questionnaires including questions
on lifestyle practices and newly diagnosed diseases such as
nephrolithiasis [22]. Additional information was obtained from
self-reported cases including symptoms and kidney stone type. In
validation studies, permission to obtain medical records was
requested from newly diagnosed cases in all three cohorts. The
diagnosis of stone disease was confirmed in over 90% of these
cases. Twenty-four-hour urine collections were obtained from
participants with a history of confirmed nephrolithiasis and from
randomly selected controls. Those with a history of kidney stones
performed the collections after the diagnosis. All 24-hour urine
collections were performed using the Mission Pharmacal system
(San Antonio, TX, USA). Urinary Ca
2+ was measured by an
atomic absorption spectrophotometer [22]. Approximately 10% of
individuals with the highest and lowest values of 24-hour urinary
Ca
2+ excretion from available male and female participants in
equal numbers were selected.
This study was approved by the Brigham and Women’s
Hospital’s institutional review board (approval # 2000P001316).
The institutional review board (IRB) specifically considered the
risks and anticipated benefits, if any, to participants, and the
selection, safety and privacy of individuals. Implied consent was
considered as appropriate by the IRB for this specific study.
B. DNA samples
DNA samples were collected as part of a general collection of
blood samples in the three cohort studies. We limited this study to
those who self-reported their race as Caucasian (and this was
confirmed as part of a separate GWAS analysis). High quality
DNA was extracted (Dana Farber/Harvard Cancer Center) from
buffy coats via QIamp 96 spin-protocol (Quiagen Inc., Chats-
worth, CA). DNA concentrations were calculated in 96-well
format using a Molecular Dynamics spectrophotometer. The 960
DNA samples were ranked by urinary Ca
2+ excretion and grouped
into pools of 15 or 20 samples prior to target DNA capture. A pilot
project testing pooled samples of 15 versus 20 individual samples
did not show any differences in DNA capture efficiency and
sequence coverage per individual samples between the pools (data
not shown). We subjected 52 sample pools (N=960 individuals; 16
pools of 15 samples and 36 pools of 20 samples) to RainDance
target (RDT) DNA capture (Table 1). The amount of genomic
DNA provided for RDT capture per pool was 10 mg (0.5–0.66 mg
per individual sample).
C. Candidate genes
Candidate genes were selected by searching public databases
(PubMed and Online Mendelian Inheritance in Man (OMIM)).
We limited the number of genes to 40 due to cost and technical
limitations at the time of study design. Our priority was to achieve
sufficient sequence coverage (at least 206) to detect rare allelic
variation. Selection of candidate genes was based on in vivo and in
vitro evidence of regulating Ca
2+ homeostasis in bone, kidney or
intestine. We also selected some genes, such as oxalate and citrate
exchangers, which may affect calcium-based stone formation by
changing supersaturation rather than urinary Ca
2+ excretion per
se. The genes resequenced in this study are listed in Table 2,
including gene name, gene/protein function, RefSeq ID and exon
number. References underlining the rationale of gene selection are
provided. As an additional gene, we included PIK3C2G (phospho-
inositide-3-kinase, class 3, gamma polypeptide) based on our
unpublished GWAS data. PIK3C2G regulates diverse cellular
responses, such as cell proliferation, oncogenic transformation, cell
migration, intracellular protein trafficking, and cell survival.
D. Primer design
Our list of the 40 genes was provided to RainDance
Technologies (RDT) (Lexington, MA) for custom primer design
based on the Primer3 algorithm (http://frodo.wi.mit.edu/
primer3). The custom panel was prepared and primers were
designed to target all 497 exons of the 40 candidate genes,
including ,50 bp of intronic sequence flanking each exon. The
795 amplicons in the panel ranged in size from 200 to 600 bases,
with a GC content of 25% to 87%, and represented a total coding
sequence of ,182 kb. All single nucleotide polymorphisms (SNPs)
and repeat regions were filtered from the primer selection region.
The RDT design was quality checked to ensure that none of the
primers were designed over known SNPs and primer sequences
were verified to avoid repetitive regions of the genome using the
program RepeatMasker (http://www.repeatmasker.org). The
primers for the 795 amplicons varied in annealing temperature
from 57uCt o6 0 uC, with a primer length range of 15 to 22 bases.
Other rules for primer design included BLASTing the primers to
the chromosome that contained the gene of interest and in silico
PCR to match the designed primers to PCR product and target
sequence.
E. Enrichment of target DNA for sequencing
The capture was performed at two laboratories, RDT in
Lexington, MA, and Ambry Genetics in Aliso Viejo, CA. DNA
samples were fragmented to 3 to 4 kb by shearing the genomic
DNA with the Covaris S2 instrument (Covaris, Woburn, MA)
following the manufacturer’s instructions. To prepare the input
DNA template mixture for targeted amplification, 3 mg of the
purified genomic DNA fragments were added to 4.7 mL of high-
fidelity buffer (Invitrogen, Carlsbad, CA), 1.26 mL of magnesium
sulfate (Invitrogen), 1.6 mL of 10 mmol/L dNTP (Invitrogen),
3.6 mL of 4 mol/L betaine (Sigma-Aldrich, St. Louis, MO), 3.6 mL
of Droplet Stabilizer (RDT, Lexington, MA), 1.8 mL of dimethyl
sulfoxide (Sigma-Aldrich), and 0.7 mL of 5 units/mL of Platinum
High-Fidelity Taq (Invitrogen). The samples were brought to a
final volume of 25 mL with nuclease-free water. PCR droplets were
generated on the RDT1000 instrument. The enrichment panel
consisted of an emulsion that contained a collection of unique
primer droplets in which each primer droplet contained a single
matched forward and reverse primer for each amplicon in the
panel. Each panel contained multiple replicates of each unique
primer droplet with consistent volume. The RDT1000 generated a
PCR droplet by pairing a single genomic DNA template droplet
Role of Allelic Variation in Calcium Excretion
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electrode in the RDT chip and were instantly merged to create a
single PCR droplet. All of the resulting PCR droplets were
dispensed as an emulsion into a PCR tube and then transferred to
a standard thermal PCR cycler for amplification (Gene-Amp 9700
thermocycler, Applied Biosystems, Foster City, CA). After PCR
amplification, the emulsion was broken to release each individual
amplicon from the PCR droplets. For each sample, an equal
volume of Droplet Destabilizer (RDT) was added to the emulsion
of PCR droplets, the sample was vortexed for 15 sec, and spun in a
microcentrifuge at 13,0006 g for 5 min. The oil below the
aqueous phase was carefully removed from the sample and the
remaining sample was purified using a MinElute column (Qiagen,
Valencia, CA) following the manufacturer’s recommended proto-
col. The purified amplicon DNA was tested on an Agilent
Bioanalyzer (Agilent Technologies, Santa Clara, CA) to confirm
that it matches the expected amplicon profile (mixture of
amplicons ranging from 200 to 600 bp in size).
F. Targeted deep DNA sequencing
A simplified schematic illustration of our emulsion-based
droplet PCR approach and the off-chip work flow before high-
throughput sequencing is presented in Figure 1. Successfully
enriched sample pools were barcoded and sequenced on the
Hiseq2000 Illumina platform (7 barcoded sample pools per lane).
After PCR purification, amplified fragments for each individual
were repaired to blunt ends using NEB Quick blunting kit (NEB,
catalog # E1201L, 15 min RT). The PCR fragments were then
linked using NEB Quick ligation kit (NEB, catalog # M2200L).
Ligation was done overnight at 25uC. The ligated products were
made into 100 mL volume by adding elution buffer and were then
sheared using Covaris E210 (Covaris, Woburn, MA). The sheared
fragments were purified using Qiagen QIAquick PCR purification
column and eluted in 32 mL of elution buffer. The samples then
entered the standard Illumina Genome Analyzer multiplex library
introduced preparation protocol. The enrichment was confirmed
by running an Agilent BioAnalyzer 7500 DNA chip. A quanti-
tative PCR was done to quantitate the library using KAPA Library
quantification kit (KAPA Biosystems, Woburn, MA, USA, catalog
# KK4824). Enriched DNA was denatured and diluted to a
concentration of 8 pM. Seventy bp single end sequencing was
performed using standard IGAII manuals and version 4 kits.
Seven sample pools per lane of Illumina sequencing were
multiplexed. After sequencing, the reads consisting of 795
fragments covering 262,545 bases were mapped and variants sites
identified against the reference sequence using the BWA software
[23]. This region is larger than the actual targeted bases (182,345)
as RDT included some intronic and intergenic regions to facilitate
primer picking. All sequence data aligned for the analysis had
sequence coverage exceeding 20-fold. Sequences were compared
to those reported by HapMap using a custom perl script to assess
the rates of data completion and accuracy. The HapMap data was
assumed to be without error when estimating data accuracy.
G. Variant identification
Utilizing the Syzygy software [24], we compared all identified
single nucleotide variants (SNVs) with three publically available
SNP databases including dbSNP (http://www.ncbi.nlm.nih.gov/
projects/SNP/), 1000 Genome Project (1000G) [25], and Exome
Sequencing Project (ESP) (http://evs.gs.washington.edu/EVS/)
databases. After filtering known SNPs, we used the transition to
transversion ratio (Ti/Tv) to filter out false positive novel variants,
which occur frequently on high-throughput sequencing platforms.
Ti/Tv can be used to estimate true-positive (TP) to false-positive
(FP) SNP data [26]. A transition is the mutation of a purine
nucleotide to another purine (A,-.G) or a pyrimidine to another
pyrimidine (C,-.T). In contrast, a transversion (Tv) substitutes a
purine for a pyrimidine or vice versa. The initially observed Ti/Tv
ratio in our SNV data was a mixture of true-positive and false-
positive SNVs. This was based on the assumption that if all
detected SNVs are true, Ti/Tv equals ,3.3. If all SNVs are false
Ti/Tv equals 0.5. We assumed that common novel variants were
most likely artifacts of sequencing. We therefore considered novel
variants only if they were observed less than or equal to 3 times in
the whole dataset. In nature, Tis are more common than Tvs. We
used the following equation to estimate the number of true positive
SNVs: %TP=(Ti/Tvobs-Ti/TvFP)/(Ti/TvTP-Ti/TvFP). Con-
sidering that Ti/TvTP is around 2.8–3.3, the %TP should be ,9–
11%.
Results
In order to query the potential relevance of rare allelic variation
in genes associated with urinary Ca
2+ excretion, we decided to
amplify and sequence the exons of 40 genes in 960 well-
characterized individuals from the NHS and HPFS populations
as outlined in the methods section (see Tables 1 and 2, Figure 1)
Efficacy of DNA enrichment and sequencing
Forty-two out of 52 samples pools were successfully captured
(N=730 individual samples). Ten sample pools (N=230) failed
enrichment due to technical issues. The 42 samples pools were
barcoded and further pooled (in sets of 7 sample pools) for
sequencing on the HiSeq2000 Illumina platform. Eight samples
pools had insufficient sequence coverage (,2-fold). Thirty four
sample pools (N=615) showed sequencing data with .20-fold
sequence coverage. These raw sequence data were deposited into
the NIH short read archive (SRA) database (http://www.ncbi.
Table 1. DNA pooling strategy for 960 individuals with low (n=480) vs. high (n=480) urinary Ca
2+ excretion.
Cohort No. of pools (sets of 15+20 samples) No. of individuals
NHS I, low urinary Ca
2+ 7( 4 615+3620) 120
NHS II, low urinary Ca
2+ 6( 6 620) 120
HPFS, low urinary Ca
2+ 13 (4615+9620) 240
NHS I, high urinary Ca
2+ 7( 4 615+3620) 120
NHS II, high urinary Ca
2+ 6( 6 620) 120
HPFS, high urinary Ca
2+ 13 (4615+9620) 240
NHS=Nurses’ Health Study; HPFS=Health Professional Follow-up Study.
doi:10.1371/journal.pone.0071885.t001
Role of Allelic Variation in Calcium Excretion
PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e71885nlm.nih.gov/sra) under the accession number PRJNA209216. The
target DNA showed uniform amplification across all target
amplicons.
The distribution of study participants with .20-fold sequence
coverage from the three cohorts in low (N=355) and high
(n=260) urinary calcium excretion groups are shown in Table 3.
The phenotype data provided include urinary solute excretion, age
and body mass index (BMI). The number of kidney stone formers
was significantly higher in the high urinary Ca
2+ group (n=164 vs.
n=96; Chi Square P value=0.004).
Allelic variation in targeted DNA sequence
Samples pools that passed our quality matrix, by enriching for
target DNA and showing over 20-fold sequence coverage, were
included in our analysis (N=615 individuals). The total number of
identified sequence nucleotide variants (SNVs) with Szygy software
was 1,572 (Figure 2A). Of these, 429 were known SNPs based on
Table 2. Candidate genes included in the resequencing study (n=40).
Gene Gene name/protein function RefSeq ID Exons
Aconitase [32] Catalyzes the isomerization of citrate to isocitrate NM_001098 18
CaSR [33] Calcium-sensing receptor NM_000388 7
Citrate lyase [34] Catalyzes the formation of acetyl-CoA from citrate NM_001096 29
Claudin 2 [35] Tight junction protein, proximal tubule (PT) NM_001171092 2
Claudin 8 [35] Tight junction protein, primarily distal nephron (DCT) NM_99328 1
Claudin 10 [36] Tight junction protein, thick ascending limb (TAL) and intestine NM_001160100 5
Claudin 14 [37] Tight junction protein, TAL NM_001146077 3
Claudin 16 [15] Tight junction protein, TAL NM_006580 4
Claudin 19 [30] Tight junction protein, TAL and DCT NM_001123395 5
CLCN5 [38] Chloride channel 5, mutations cause Dent’s disease NM_000084 15
CLCNKA [39] Basolateral chloride channel expressed in TAL NM_001042704 20
CLCNKB [40] Basolateral chloride channel expressed in TAL and DCT; mutation cause type III Bartter’s syndrome NM_000085 20
FGF23 [41] Fibroblast growth factor 23, phosphatonin NM_020638 3
GCMB [42] Glial cell missing B, mutations cause familial isolated hypoparathyroidism NM_004752 5
Klotho [43] Regulator of TRPV5 and FGF23 NM_004795 5
NHERF1 [44] Hydrogen exchanger regulatory factor 1, mutations cause hypophosphatemia and nephrolithiasis NM_004252 6
NHERF2 [45] Hydrogen exchanger regulatory factor 2, expressed like NHERF1 in PT NM_001130012 7
NKCC2 [46] Na
+-K
2-2Cl
2-cotransporter, mutations cause type 1 (neonatal) Bartter’s syndrome NM_000220 27
PDZK1 [47] Hydrogen exchanger regulatory factor 3, PT NM_002614 10
PIK3C2G Phosphoinositide-3-kinase, class 3, c polypeptide NM_004570 32
PTH [48] Parathyroid hormone NM_000315 3
PTHR [49] Parathyroid hormone receptor 1 NM_000316 16
ROMK [50] Renal outer medullary K
+ channel, mutations cause type 2 Bartter’s syndrome NM_000338 4
SLC12A3 [51] Thiazide-sensitive Na
+-Cl
2 cotransporter, mutation cause Gitelman’s syndrome NM_000339 26
SLC13A2 [52] Na
+ citrate transporter NaC1 NM_001145975 12
SLC13A3 [53] Na
+ citrate transporter NaC2 NM_001193340 14
SLC25A1 [54] Mitochondrial citrate transporter NM_005984 9
SLC26A1 [55] Oxalate and sulfate anion transporter NM34425 4
SLC26A2 [56] Oxalate and citrate exchanger NM_000112 2
SLC26A6 [57] Oxalate and citrate exchanger NM_001040454 21
SLC34A1 [58] Na
+ phosphate co-transporter NaPi2A NM_003052 13
SLC34A3 [59] Na
+ phosphate co-transporter NaPi2C NM_001177316 13
SLC4A1 [60] AE1 oxalate, mutations cause distal RTA NM_000342 20
SLC4A2 [61] AE2 oxalate NM_003040 23
SLC4A3 [61] AE3 oxalate NM_005070 23
TRPV5 [62] Epithelial Ca
2+ channel ECaC1 NM_019841 14
TRPV6 [63] Epithelial Ca
2+ channel ECaC2 NM_018646 15
UMOD [64] Uromodulin NM_001008389 11
VDR [65] Vitamin D receptor NM_000376 11
WNK4 [66] Protein kinase, lysine deficient 4, mutations cause pseudohypoaldosteronism type 2 NM_032387 19
doi:10.1371/journal.pone.0071885.t002
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and ESP databases) (Figure 2B). The Ti/Tv of these known SNPs
(2.88) differed from the Ti/Tv of the 1,572 SNVs discovered in
our study population (0.75). This finding suggested a significant
portion of false-positive SNVs. The number of novel variants was
reduced to 259 after exclusion of novel SNVs, which were seen 4
or more times and were not present in the tested databases
(N=884, Ti/Tv 0.5). The Ti/Tv of novel allelic variants
improved from 0.75 to 2.8, which is both within the expected
range of Ti/Tv in naturally occurring mutations (,2.8–3.3) and
similar to the Ti/Tv of the 429 known SNPs (2.88) identified in
this study. Table S1 lists all identified novel SNPs (n=259)
including information on chromosomal location, nucleotide
substitution, and effect on protein sequence. Novel silent, nonsense
and missense SNPs with existing RefSeq accession numbers were
deposited into the NCBI ClinVar database (https://www.ncbi.
nlm.nih.gov/clinvar/). ClinVar accession IDs are provided in
Table S1.
SNP data for Claudin14
Table 4 lists all CLDN14 variations identified in our sample
set. SNP rs113831133 was more common among individuals in
the lower (29 out of 710 haplotypes; 4.1%) compared with the
higher (6 out of 520 haplotypes; 1.1%) urinary Ca
2+ excretion
group (Fisher’s exact test: P value=0.003). When adjusted for
multiple comparisons with Bonferroni’s correction (for n=429
known SNPs), our finding for rs113831133 did not reach statistical
significance (required P value ,0.0001). SNP rs11381133 did not
vary by sex (17/650 in females, 2.6%, vs. 18/580 in males, 3.1%,
P value=0.61). The common, synonymous CLDN14 SNP
rs219780, previously shown to be associated with kidney stone
disease in a large GWAS study [27], did not differ between the two
urinary Ca
2+ groups (unadjusted P value=0.82).
Discussion
The goal of this work was to quantify the frequency of rare,
presumably functional genetic variants in individuals with lower
and higher urinary Ca
2+ excretion because urinary Ca
2+ is a major
risk factor for calcium-based kidney stone disease [4]. A different
approach has been pursued previously in a large GWAS for kidney
stone disease and has shown only limited success possibly due to
the complex mechanistic nature of nephrolithiasis. That GWAS in
3,773 kidney stone cases and 42,510 controls from Iceland and the
Netherlands reported an association of CLDN14 with nephroli-
thiasis. The synonymous CLDN14 variant rs219780(C) (minor
allele frequency ,20%) showed a significant association with
kidney stone disease (P value=4610
212) and low bone mineral
density (for the hip P value=0.00039) [27].
In this study, we tested the association of the frequencies of rare
allelic variants with possible effect on urinary Ca
2+ excretion by
resequencing 40 known genes that could potentially affect or
correlate with urinary Ca
2+ excretion either in human disease or
animal models. Our main hypothesis was that differing number of
rare variants between individuals with lower and higher urinary
Ca
2+ excretion would be identified in at least some of these
candidate genes. Rare, non-synonymous variants in low and high
urinary Ca
2+ excretion groups could contribute to the level of
urinary Ca
2+ excretion (lowering or increasing excretion and
thereby protecting from or predisposing to calcium-based stone
formation). This approach has succeeded for other phenotypes
such as hyperlipidemia [18],[19] and non-alcoholic fatty liver
disease [20], where the frequency of rare gene variants was
significantly different in the extremes of the studied phenotype.
The results in those studies were consistent with in silico predictions
that rare amino acid changing sequence variations found in
healthy individuals are as deleterious to protein function as gene
mutations causing Mendelian disease. Such sequence variations
may explain a significant fraction of phenotypic variation in
human as suggested for blood pressure variation in the Framing-
ham Heart Study population [21].
We identified 1,572 single nucleotide variants (SNVs), most of
which appeared common in our subjects. Initially, we filtered out
known gene variants based on three large SNP databases and then
applied a simple but very efficient method the Ti/Tv of naturally
occurring mutations [26]. We filtered potentially false-positive
SNVs, significantly reducing the initially seen number of SNVs
and improving the Ti/Tv from 0.75 to a ‘‘normal’’ range of 2.88.
Figure 1. Simplified schematic illustration of the study design
utilizing emulsion-based droplet PCR technology and next-
generation sequencing.
doi:10.1371/journal.pone.0071885.g001
Table 3. Study participants with successful DNA target amplification and sequencing.
Lower urinary Ca
2+ excretion n=355 (range 18–165
mg/day)
Higher urinary Ca
2+ excretion n=260 (range 210–465
mg/day)
Stone formers n=182 Non-stone formers n=173 Stone formers n=164* Non-stone formers n=96
Ca
2+ (mg/day) 100637 101635 320657 309656
Age (years) 64611 61685 9 610 6068
BMI (kg/m
2)2 8 662 6 652 8 652 7 65
The frequency of kidney stone formers was significantly higher (*) in the high urinary Ca
2+ group (Chi Square P value=0.004).
doi:10.1371/journal.pone.0071885.t003
Role of Allelic Variation in Calcium Excretion
PLOS ONE | www.plosone.org 5 August 2013 | Volume 8 | Issue 8 | e71885Of the 259 novel SNPs in 40 different genes, none showed a
significantly increased frequency in the low versus the high urinary
Ca
2+ excretion groups. These extremely rare candidate gene
variants identified mostly in single individuals could be function-
ally contributing to the level of urinary Ca
2+ excretion, because
they are mostly amino acid changing and occur frequently only in
one of the two groups with extreme urinary Ca
2+ excretion.
Identification of the individuals carrying these very rare variants
and testing their relatives (for degree of urinary Ca
2+ excretion and
presence of variant) would help to answer if these variants
contribute to the phenotype. Examining the conservation of the
affected residue across species as well as the in vitro and in vivo
effects on gene function would be necessary to postulate a cause-
effect relation for these very rare variants.
We also analyzed our data for rare variants with allele frequency
of 2–5%. Of these, the non-synonymous CLDN14 SNP
rs113831133 (minor allele frequency for ,3.3% for c.11C.T,
p.Thr4Met, dbSNP) showed a lower allele frequency in individuals
with high urinary Ca
2+ excretion (,1.1% vs. 4.1% in the lower
urinary Ca
2+ group), suggesting that if present it may lower
urinary Ca
2+ excretion, probably by decrease in CLDN14
function. The functional significance of the CLDN14 SNP
rs113831133 in the thick ascending limb is unknown. Since
heterozygous CLDN14-deficient mice have no renal phenotype, a
dominant negative effect of rs113831133 appears more likely than
haploinsufficiency [28]. The rs113831133 finding is in particular
interesting since the synonymous CLDN14 SNP rs219780 has
been implicated previously in kidney stone disease [27]. The
frequency of this SNP was not significantly different in our study
groups, though our study included a smaller sample size and our
focus was on urine Ca
2+ excretion rather than kidney stone
formation. There are several different studies implicating an
Figure 2. The flowchart data analysis of identified sequence nucleotide variants (SNVs) (A). After identifying known SNPs utilizing
publically available databases (SNP distribution shown in B), false-positive SNVs were filtered based on frequency in our dataset (present four or more
times). The transition to transversion ratio (Ti/Tv) of naturally occurring SNPs supported this analytical approach. dbSNP=Single Nucleotide
Polymorphism Database; 1000G=1000 Genome Project; ESP=Exome Sequencing Project.
doi:10.1371/journal.pone.0071885.g002
Table 4. Distribution of all identified Claudin14 SNPs in the low and high urinary Ca
2+ excretion groups with unadjusted Chi
square P values.
Chr. Position SNP ID (rs…) SNP class Nucleotide Low urine Ca
2+ High urine Ca
2+ P
37833330 . missense c.664G.T 2.2% (16/710) 1.5% (8/520) 0.41
37833331 . silent c.663G.A 0.0% (0/710) 0.2% (1/520) -
37833934 . silent c.60C.T 0.1% (1/710) 0.2% (1/520) -
37833931 117560775 silent c.63G.A 1.4% (10/710) 3.2% (17/520) 0.03
37833694 113350364 silent c.300C.T 0.4% (3/710) 0.0% (0/520) -
37833699 . missense c.295G.A 0.0% (0/710) 0.3% (1/520) -
37833751 219779 silent c.243C.T 24.2% (172/710) 23.8% (124/520) 0.89
37833979 . silent c.15C.T 0.0% (0/710) 0.2% (1/520) -
37833809 . missense c.185A.G 0.4% (3/710) 0.0% (0/520) -
37833892 . silent c.102G.A 0.1% (1/710) 0.0% (0/520) -
37833865 . silent c.129C.T 0.3% (2/710) 0.0% (0/520) -
37833506 . missense c.488C.T 0.3% (2/710) 0.2% (1/520) -
37833983 113831133 missense c.11C.T 4.1% (29/710) 1.1% (6/520) 0.003
37833976 . silent c.18G.A 0.3% (2/710) 0.0% (0/520) -
37833661 74934405 silent c.333A.C 4.1% (29/710) 4.4% (23/520) 0.77
37833304 . silent c.690C.T 0.1% (1/710) 0.1% (1/520) -
37833307 219780 silent c.687G.A 18.4% (131/710) 18.9% (98/520) 0.82
The missense variant rs113831133, highlighted in bold, was more frequent among individuals with lower urinary Ca
2+ excretion. This association did not reach statistical
significance when adjusted for multiple comparisons.
doi:10.1371/journal.pone.0071885.t004
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2+ excretion. CLDN14
has been shown to be a negative regulator of the CLDN16/19
complex in the TAL, which has an important role in the
paracellular Ca
2+ reabsorption in the TAL [28]. Mutations in both
CLDN16 and 19 have been shown to cause familial hypercalciuria
in human. In addition, recent animal studies showed a significant
role for CLDN14 in urinary Ca
2+ reabsorption [29,30]. Homo-
zygous CLDN14-deficient mice display lower urinary Ca
2+
excretion than wild-type controls when challenged with a high
calcium diet [28]. Renal tubule-specific Casr-deficient mice
display decreased urinary Ca
2+ excretion compared to control
animals. CLDN14 is significantly downregulated (,80%) in this
mouse model [31].
Our study had several limitations. The selection of candidate
genes was biased and several other candidate genes potentially
related to urinary Ca
2+ excretion were not included in our
investigation. Therefore, an unbiased approach including all genes
would be most favorable. This could be accomplished by exome
capture followed by next-generation sequencing including all
coding regions of the genome. Another limitation is the relatively
low sample number reducing the power to test the main hypothesis
of this study. In order to further examine the role of rare,
potentially functional variants, e.g. with minor allele frequency of
1% or lower, a larger sample group is needed. Our study was
designed to include sequencing data of 960 individuals, however,
due to technical difficulties we were only able to include 615
samples.
Conclusions
Our study does not support the hypothesis that rare, presum-
ably functional allelic variants in the tested genes influence urinary
Ca
2+ excretion. Although an association of CLDN14 with urinary
Ca
2+ excretion was observed, this finding didn’t reach statistical
significance. Yet, our data combined with the previous GWAS,
recent human and animal data suggest a potential role for
CLDN14 in urinary Ca
2+ excretion. Further studies of CLDN14
are required to study its contribution to urinary Ca
2+ excretion
and calcium-based kidney stone disease.
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